Stocks News

LAST PRICE
17.9100
TODAY'S CHANGE (%)
Trending Down-0.9600 (-5.0874%)

Bid / Lots
17.9500/ 3
Ask / Lots
20.0000/ 20
Open / Previous Close
19.4200 / 18.8700
Day Range
Low 17.5800
High 19.8000
52 Week Range
Low 11.6650
High 42.6000
Volume
106,450
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Yesterday
- DJ Cartesian Therapeutics Price Target Maintained With a $41.00/Share by Needham, from 17 hours ago by Dow Jones
  17 hours ago by Dow Jones
  Companies Mentioned: RNAC
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/RNAC/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 25, 2024 07:24 ET (12:24 GMT)
Nov 21, 2024
- Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit, from 7:00AM ET on Thursday Nov 21, 2024 by Dow Jones
  7:00AM ET on Thursday Nov 21, 2024 by Dow Jones
  Companies Mentioned: RNAC
  
  Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit
Nov 8, 2024
- DJ Cartesian Therapeutics Is Maintained at Buy by HC Wainwright & Co., from 2:26PM ET on Friday Nov 08, 2024 by Dow Jones
  2:26PM ET on Friday Nov 08, 2024 by Dow Jones
  Companies Mentioned: RNAC
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/RNAC/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 08, 2024 14:26 ET (19:26 GMT)
- Cartesian Therapeutics Announces New Employment Inducement Grants, from 7:05AM ET on Friday Nov 08, 2024 by Dow Jones
  7:05AM ET on Friday Nov 08, 2024 by Dow Jones
  Companies Mentioned: RNAC
  
  Cartesian Therapeutics Announces New Employment Inducement Grants
  
  FREDERICK, Md., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to two new employees. On November 4, 2024, the Company issued to these employees options to purchase an aggregate of 4,854 shares of the Company's common stock with an exercise price of $19.11, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. The option vests as to 25% on November 4, 2025, and then in three equal annual installments thereafter such that the options will be fully vested on November 4, 2028. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees' entry into employment with the Company.
- DJ Cartesian Therapeutics Price Target Maintained With a $41.00/Share by Needham, from 5:01AM ET on Friday Nov 08, 2024 by Dow Jones
  5:01AM ET on Friday Nov 08, 2024 by Dow Jones
  Companies Mentioned: RNAC
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/RNAC/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 08, 2024 05:01 ET (10:01 GMT)

Nov 24, 2024
- Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors, from 7:28PM ET on Sunday Nov 24, 2024 by PR Newswire
  7:28PM ET on Sunday Nov 24, 2024 by PR Newswire
  Companies Mentioned: TLPH, MGTX, OLMA
- Press Release: Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors, from 7:27PM ET on Sunday Nov 24, 2024 by Dow Jones
  7:27PM ET on Sunday Nov 24, 2024 by Dow Jones
  Companies Mentioned: TLPH, MGTX, OLMA
- Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors, from 7:27PM ET on Sunday Nov 24, 2024 by Dow Jones
  7:27PM ET on Sunday Nov 24, 2024 by Dow Jones
  Companies Mentioned: TLPH, MGTX, OLMA
Nov 18, 2024
- DJ MeiraGTx Holdings Is Maintained at Buy by Chardan Capital, from 5:16PM ET on Monday Nov 18, 2024 by Dow Jones
  5:16PM ET on Monday Nov 18, 2024 by Dow Jones
  Companies Mentioned: MGTX
Nov 15, 2024
- DJ Taysha Gene Therapies Is Maintained at Buy by Canaccord Genuity, from 9:41AM ET on Friday Nov 15, 2024 by Dow Jones
  9:41AM ET on Friday Nov 15, 2024 by Dow Jones
  Companies Mentioned: TSHA
Nov 14, 2024
- DJ Taysha Gene Therapies Is Maintained at Buy by Chardan Capital, from 5:51PM ET on Thursday Nov 14, 2024 by Dow Jones
  5:51PM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: TSHA
- DJ Taysha Gene Therapies Price Target Maintained With a $6.00/Share by Needham, from 1:54PM ET on Thursday Nov 14, 2024 by Dow Jones
  1:54PM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: TSHA
- DJ MeiraGTx Holdings Is Maintained at Outperform by RBC Capital, from 12:11PM ET on Thursday Nov 14, 2024 by Dow Jones
  12:11PM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: MGTX
- DJ OmniAb Price Target Maintained With a $8.00/Share by Benchmark, from 9:43AM ET on Thursday Nov 14, 2024 by Dow Jones
  9:43AM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: OABI
- DJ Taysha Gene Therapies Price Target Maintained With a $7.00/Share by Cantor Fitzgerald, from 9:11AM ET on Thursday Nov 14, 2024 by Dow Jones
  9:11AM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: TSHA

Cartesian Therapeutics Inc
NASDAQ:RNACUnited States

Search Criteria

Yesterday

DJ Cartesian Therapeutics Price Target Maintained With a $41.00/Share by Needham, from 17 hours ago by Dow Jones

Nov 21, 2024

Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit, from 7:00AM ET on Thursday Nov 21, 2024 by Dow Jones

Nov 8, 2024

DJ Cartesian Therapeutics Is Maintained at Buy by HC Wainwright & Co., from 2:26PM ET on Friday Nov 08, 2024 by Dow Jones

Cartesian Therapeutics Announces New Employment Inducement Grants, from 7:05AM ET on Friday Nov 08, 2024 by Dow Jones

DJ Cartesian Therapeutics Price Target Maintained With a $41.00/Share by Needham, from 5:01AM ET on Friday Nov 08, 2024 by Dow Jones

Peers Headlines

Nov 24, 2024

Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors, from 7:28PM ET on Sunday Nov 24, 2024 by PR Newswire

Press Release: Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors, from 7:27PM ET on Sunday Nov 24, 2024 by Dow Jones

Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors, from 7:27PM ET on Sunday Nov 24, 2024 by Dow Jones

Nov 18, 2024

DJ MeiraGTx Holdings Is Maintained at Buy by Chardan Capital, from 5:16PM ET on Monday Nov 18, 2024 by Dow Jones

Nov 15, 2024

DJ Taysha Gene Therapies Is Maintained at Buy by Canaccord Genuity, from 9:41AM ET on Friday Nov 15, 2024 by Dow Jones

Nov 14, 2024

DJ Taysha Gene Therapies Is Maintained at Buy by Chardan Capital, from 5:51PM ET on Thursday Nov 14, 2024 by Dow Jones

DJ Taysha Gene Therapies Price Target Maintained With a $6.00/Share by Needham, from 1:54PM ET on Thursday Nov 14, 2024 by Dow Jones

DJ MeiraGTx Holdings Is Maintained at Outperform by RBC Capital, from 12:11PM ET on Thursday Nov 14, 2024 by Dow Jones

DJ OmniAb Price Target Maintained With a $8.00/Share by Benchmark, from 9:43AM ET on Thursday Nov 14, 2024 by Dow Jones

DJ Taysha Gene Therapies Price Target Maintained With a $7.00/Share by Cantor Fitzgerald, from 9:11AM ET on Thursday Nov 14, 2024 by Dow Jones